Skip to main content
padlock icon - secure page this page is secure

Small Molecules Effective Against Liver and Blood Stage Malarial Infection

Buy Article:

$68.00 + tax (Refund Policy)

Malaria is a lethal disease causing devastating global impact by killing more than 8,00,000 individuals yearly. A noticeable decline in malaria related deaths can be attributed to the most reliable treatment, ACTs against P. falciparum. However, the cumulative resistance of the malaria parasite against ACTs is a global threat to control the disease and, therefore the new effective therapeutics are urgently needed, including new treatment approaches. Majority of the antimalarial drugs target BS malarial infection. Currently, scientists are eager to explore the drugs with potency against not only BS but other life stages such as sexual and asexual stages of the malaria parasite. Liver Stage is considered as one of the important drug targets as it always leads to BS and the infection can be cured at this stage before it enters into the Blood Stage. However, a limited number of compounds are reported effective against LS malaria infection probably due to scarcity of in vitro LS culture methods and clinical possibilities. This mini review covers a range of chemical compounds showing efficacy against BS and LS of the malaria parasite’s life cycle collectively (i.e. dual stage activity). These scaffolds targeting dual stages are essential for the eradication of malaria and to evade resistance.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antimalarials; Artemisinin-based combination therapy (ACT); Chloroquine (CQ) resistance; Hybrid molecules; Malaria; Plasmodium falciparum (Pf)

Document Type: Review Article

Publication date: September 1, 2018

This article was made available online on December 12, 2018 as a Fast Track article with title: "Small Molecules Effective Against Liver and Blood Stage Malarial Infection".

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more